Stocktoria
SOLIGENIX, INC. SNGX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1994-04-04
SOLIGENIX, INC. statistics & valuation
Market cap$6.1M
P / B1.1×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | — | — | 11.6% | 42.0% | 11.6% |
| Operating margin | — | -7907.7% | -917.1% | -1500.6% | -1589.2% |
| Net margin | — | -6925.1% | -731.6% | -1454.1% | -1522.7% |
| Return on assets | -120.0% | -92.2% | -62.7% | -96.6% | -46.7% |
| Return on equity | -209.4% | -200.7% | -243.4% | 558.5% | -117.1% |
| Debt / equity | — | 0.00× | 0.40× | -0.00× | — |
| Current ratio | 2.39 | 1.82 | 1.55 | 0.84 | 4.22 |
| Revenue growth | — | -85.8% | -11.5% | 15.1% | -65.1% |
Source: SEC EDGAR filings · CIK 0000812796 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.